The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Prime Medicine Inc (NASDAQ: PRME) was $1.34 for the day, down -16.04% from the previous closing price of $1.59. In other words, the price has decreased by -$16.04 from its previous closing price. On the day, 9.56 million shares were traded.
Ratios:
Our analysis of PRME’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.78 and its Current Ratio is at 4.78. In the meantime, Its Debt-to-Equity ratio is 1.13 whereas as Long-Term Debt/Eq ratio is at 1.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, JMP Securities on December 10, 2024, initiated with a Mkt Outperform rating and assigned the stock a target price of $10.
On May 20, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.
Citigroup Upgraded its Neutral to Buy on May 16, 2024, while the target price for the stock was maintained at $10.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 45.53 while its Price-to-Book (P/B) ratio in mrq is 1.64.
Stock Price History:
Over the past 52 weeks, PRME has reached a high of $8.27, while it has fallen to a 52-week low of $1.12. The 50-Day Moving Average of the stock is -16.94%, while the 200-Day Moving Average is calculated to be -55.48%.
Shares Statistics:
A total of 131.16M shares are outstanding, with a floating share count of 51.97M. Insiders hold about 60.42% of the company’s shares, while institutions hold 28.62% stake in the company.
Earnings Estimates
Prime Medicine Inc (PRME) is currently under the scrutiny of 9.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.25 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$1.04 and -$1.37 for the fiscal current year, implying an average EPS of -$1.21. EPS for the following year is -$0.93, with 10.0 analysts recommending between -$0.67 and -$1.4.
Revenue Estimates
A total of 10 analysts have provided revenue estimates for PRME’s current fiscal year. The highest revenue estimate was $50M, while the lowest revenue estimate was $1.45M, resulting in an average revenue estimate of $16.9M. In the same quarter a year ago, actual revenue was $2.98M
